Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 9Phase 1 3Phase NA 1Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Unknown 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 1

Interventions

pembrolizumab 126Carboplatin 108Pemetrexed 76Paclitaxel 76Cisplatin 73Nivolumab 56Docetaxel 53Erlotinib Hydrochloride 50Gemcitabine 49Radiotherapy 48Bevacizumab 32osimertinib 31Cetuximab 29atezolizumab 25Cyclophosphamide 25durvalumab 24130-nm albumin-bound paclitaxel 22Oxaliplatin 19Fluorouracil 18Taxes 17Radiosurgery 17fludarabine 16Magnetic Resonance Spectroscopy 16Gefitinib 16Ipilimumab 15Vinorelbine 14Leucovorin 14Albumin-Bound Paclitaxel 14Vorinostat 13Radiation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Non-Small-Cell Lung × aumolertinib × Clear all
NCT07130916 2025-08-19

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05430386 2023-02-14

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Unknown
174 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05223595 2022-02-04

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1 Unknown
42 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡